Skip to content

Ultragenyx Pharmaceutical RARE Intangible Purchases

Intangible Purchases at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$1.49M+128%
Moderna logo
ModernaMRNA
$0-100%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0-100%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$0
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$5.25M-69.8%

Other financials

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total debt$36.0M-10.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation

See full
Market cap$2.83B-39.4%
P/S4.2×-3.7×

Profitability

See full
Gross margin97.2%
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×
Current ratio-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's intangible purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's intangible purchases?
Ultragenyx Pharmaceutical (RARE) reported intangible purchases of $5M in Q1 2026.
How has Ultragenyx Pharmaceutical's intangible purchases changed year-over-year?
Ultragenyx Pharmaceutical's intangible purchases decreased by 66.7% year-over-year, from $15M to $5M.
What does intangible purchases mean?
Cash spent acquiring intangible assets such as patents, licenses, and other intellectual property.